Genmab A/S

27 trials 4 recruiting Commercial sponsor Merged from 2 name variants

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

4 Recruiting

22 Completed trials

21 Countries active

51 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (FiH)

Phase III: 4 Phase II: 5 Phase I/II: 4 Phase I: 5 Phase I (FiH): 9

Oversight events:

3 serious breaches 3 temporary halts 1 unexpected event across 5 trials

View oversight register →

100%

22 of 22 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Endometrial cancer 2 Non-small cell lung cancer metastatic 2 Non-small cell lung cancer 1 B-cell lymphoma refractory 1 Endometrial cancer recurrent 1 Neoplasm malignant 1 Endometrial cancer metastatic 1 Ovarian cancer 1 Myelodysplastic syndrome with excess blasts 1 Cervix carcinoma 1 Malignant melanoma 1

Top IMPs

EPCORITAMAB 5 PEMBROLIZUMAB 5 ACASUNLIMAB 4 RINATABART SESUTECAN 3 PACLITAXEL ALBUMIN-BOUND 2 TECAGINLIMAB 2 CARBOPLATIN 1 CISPLATIN 1 DARATUMUMAB 1 ERZOTABART 1 GEN1046 1 GEN1047 1

All trials — page 2

27 total

Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended

2023-508832-68-00 Phase I/II 6 countries TISOTUMAB VEDOTIN
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended

2023-503348-15-00 Phase I (FiH) 5 countries GEN3017
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned… Ended

2025-520468-16-00 Phase II 4 countries ACASUNLIMAB; PEMBROLIZUMAB

Showing 25–27 of 27 trials

← All sponsors A–Z